Rudolf Zechner was born in 1954 in Graz, Austria. He studied biochemistry at his hometown university, and in 1980 earned his PhD. He subsequently worked as a post-doctoral fellow at the Rockefeller University of New York. He then returned to the University of Graz and in 1998 became Professor of Biochemistry at the Institute of Molecular Biosciences, University of Graz.
A member of the Austrian Academy of Sciences, Rudolf Zechner has already received numerous prestigious awards, in particular the Wittgenstein Prize, Austria’s highest scientific award, as well as an Advanced Grant from the European Research Council.
Obesity, type 2 diabetes and cardiovascular disease continue to grow unabated around the world. These disorders are often caused by dysfunctional lipid metabolism. This in turn leads to accumulations of fats and cholesterol in the liver and heart or on the walls of the arteries, resulting in malfunctions in these organs or tissues.
Rudolf Zechner and his colleagues studied the mechanisms governing the metabolism of lipids for more than 15 years and specifically focused on lipases, enzymes that degrade fats. They found that a new enzyme belonging to this family, adipose triglyceride lipase (ATGL) and its protein co-activator CGI-58, facilitate lipid catabolism in both mice and humans. In other words, these biological molecules play a crucial role in the storage and mobilisation of fats in our body. This discovery revolutionized our understanding of fat turnover. It also offered a mechanistic explanation for the occurrence of rare genetic diseases termed «neutral lipid storage diseases», caused by a deficiency of ATGL or of its protein co-activator.
More recently, Rudolf Zechner and his team sought to understand how the breakdown of fat influences cell functions and the pathogenesis of disease. They were able to show a strong correlation between the catabolism of fats and cardiac function. To their surprise, they also discovered that lipid catabolism was involved in the development of cachexia, which takes the form of an uncontrolled and irreversible loss of weight in numerous cancer patients. The Austrian researchers have thus possibly identified a new direction for the treatment of this serious condition.
“Man can learn nothing except by going from the known to the unknown” – is a quotation from the famous French physiologist Claude Bernard and archetypical for the development of the research area of Rudolf Zechner, lipid and energy metabolism. Although studied since the beginning of modern biosciences around 200 years ago, lipid and energy metabolism still remains of central interest due to its involvement in the development of extremely common diseases such as obesity, cardiovascular disease or cancer.
Animal and plant “fats” and “oils” were historically among the first biomolecules whose chemical composition was elucidated. Already during the first half of the 19th century French chemists Chevreul and Berthelot discovered that fats and oils consist of three fatty acid molecules, which are esterified with glycerol. In 1858, Bernard himself discovered an enzyme later called “lipase” that cleaves these “triglycerides” (TGs) to release fatty acids (FAs) and glycerol in a process termed “lipolysis”. The synthesis and lipolysis of TGs were recognized as essential processes in all organisms once it was understood that TGs cannot cross cell membranes. Accordingly, all fat in our nutrients must be hydrolyzed before they can be absorbed in the gut and later deposited in fat (adipose) tissue. Conversely, when fat is mobilized again from adipose tissue to supply other tissues such as heart, muscle, or liver with energy, TGs must be degraded before FAs and glycerol can be released.
Rudolf Zechner’s laboratory focuses on enzymes and mechanisms that control lipolysis in adipose tissue and other cell types. For many decades, textbook biochemistry taught that an enzyme called hormone-sensitive lipase is rate-limiting for the degradation of fat in adipose tissue. But when Zechner and colleagues eliminated this enzyme in mice, the animals unexpectedly did not accumulate fat or become obese, but instead exhibited relatively normal lipolysis. This indicated that the main enzyme for fat catabolism remained unidentified; a circumstance that led to the discovery of adipose triglyceride lipase (ATGL) by the Zechner lab. The severe fat accumulation in multiple tissues of ATGL-deficient mice soon proved the essential role of this enzyme in lipolysis. The Zechner group also demonstrated that ATGL requires a protein co-activator for full enzymatic activity called CGI-58.
The discovery of ATGL and its activation by CGI-58 finally provided a mechanistic explanation for the development of neutral lipid storage disease (NLSD) in humans, which was originally described in the 1960’s and 1970’s. Patients with this condition are characterized by the systemic accumulation of fat in multiple tissues. These symptoms clearly resembled the pathologies observed in ATGL-deficient mice. Therefore, it came as no surprise when several other groups soon reported that mutations in the genes for ATGL and CGI-58 cause various forms of NLSD. Less expected, however, was the finding that mice and humans with defective ATGL-mediated lipolysis not only accumulate fat in tissues and cells but also develop severe dysfunctions in multiple organs including the heart (ATGL-deficiency) or the skin (CGI-58 deficiency).
This complex disease profile suggested that defects in lipolysis not only regulate fat storage but also affects other metabolic pathways and energy metabolism (outlined in Fig. 1), which may be related to the pathogenesis of disease. In this context, Zechner’s laboratory was able to show that ATGL deficiency in cardiac muscle has a major impact on heart function via nuclear receptor signaling and mitochondrial function. Other quite recent results from his group demonstrated that lipolysis is involved in the pathogenesis of cancer-associated cachexia (CAC). Cachexia is a devastating condition of uncontrolled loss of adipose and muscle mass commonly observed in patients with cancer and other chronic diseases. CAC is associated with a very poor prognosis for survival. Zechner’s group showed that in the absence of ATGL, the development of CAC can be delayed in certain mouse models of cancer.
Exciting recent work of the Zechner lab uncovered a metabolic “crosstalk” between lipolysis and lipid synthesis in adipose tissue, but it is currently unknown how these processes communicate with each other on molecular terms. The Louis-Jeantet Prize will help to clarify these mechanisms and investigate how this form of crosstalk contributes to cellular and organismal (dys)function. Additionally, the grant will finance the search for currently unknown enzymes involved in lipid catabolism. The powerful combination of tremendous resources of genome data together with innovative screening methods will facilitate the discovery of new enzymes that contribute to the catabolic turnover of lipids. The medical relevance of this work is evident considering the growing prevalence of human metabolic disorders.
Fig. 1. Lipolysis and its connection to other metabolic and signaling pathways.
Lipolysis of TGs occurs on lipid droplets (yellow) via the enzymatic activities of ATGL, HSL, and MGL. Lipolysis generates FAs and glycerol. FAs and the lipolytic intermediates DGs and MGs are important signaling lipids or precursors for signaling lipids. Additionally, they are major energy substrates and precursors for the synthesis of membrane lipids. Alterations in lipolysis may alter these pathways and contribute to the development of metabolic diseases listed in red.
Abbreviations: ACSL, acyl-CoA synthetase; ATGL, adipose triglyceride lipase; CGI58, comparative gene identification-58; CoA, Coenzyme A; DG, diglyceride; FA, fatty acid; FATP, FA transport protein; HSL, hormone-sensitive lipase; MG, monoglyceride; MGL, MG lipase; TG, triglyceride;